Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryoko Yamada

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Journal of Medical Virology|March 19, 2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapyYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Cancers|July 27, 2022
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination ImmunotherapyTakayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Alimentary Pharmacology & Therapeutics|April 1, 2022
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' replyYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2019
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic responseRyoko Yamada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Gastroenterology|July 16, 2020
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis BAkihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|May 13, 2010
[Investigation of simplified international diagnostic criteria for autoimmune hepatitis]Akira Kaneko, Mitsuhiko Kubo, Ryoko Yamada, et al.
Journal of Gastroenterology|April 21, 2026
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 yearsTetsuya Hosaka, Hayato Hikita, Yuki Tahata, et al.
Journal of Gastroenterology|July 31, 2015
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirinYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Journal of Medical Virology|March 19, 2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapyYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Cancers|July 27, 2022
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination ImmunotherapyTakayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Alimentary Pharmacology & Therapeutics|April 1, 2022
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' replyYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2019
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic responseRyoko Yamada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Gastroenterology|July 16, 2020
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis BAkihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|May 13, 2010
[Investigation of simplified international diagnostic criteria for autoimmune hepatitis]Akira Kaneko, Mitsuhiko Kubo, Ryoko Yamada, et al.
Journal of Gastroenterology|April 21, 2026
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 yearsTetsuya Hosaka, Hayato Hikita, Yuki Tahata, et al.
Journal of Gastroenterology|July 31, 2015
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirinYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Pageof 9